Zoledronic acid inhibits the development of osteolytic bone disease and increases disease free survival in a murine model of multiple myeloma.

Zoledronic acid inhibits the development of osteolytic bone disease and increases disease free survival in a murine model of multiple myeloma.

Detalhes bibliográficos
Principais autores:	Croucher, P, Hijzen, A, Shipman, C, Perry, M, Lippitt, J, Green, J, Van Camp, B, Vanderkerken, K
Formato:	Journal article
Publicado em:	2001

Registros relacionados

Zoledronic acid prevents the development of osteolytic bone disease and increases survival in a murine model of multiple myeloma
por: Croucher, P, et al.
Publicado em: (2002)

Zoledronic acid prevents the development of myeloma bone disease and increases survival
por: Shipman, C, et al.
Publicado em: (2002)

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.
por: Croucher, P, et al.
Publicado em: (2001)

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
por: Croucher, P, et al.
Publicado em: (2001)

Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.
por: Croucher, P, et al.
Publicado em: (2003)

Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma.
por: Croucher, P, et al.
Publicado em: (2000)

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
por: Croucher, P, et al.
Publicado em: (2003)

Osteoprotegerin and the development of myeloma bone disease
por: Croucher, P, et al.
Publicado em: (2004)

The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma.
por: Shipman, C, et al.
Publicado em: (2000)

Myeloma cells can down-regulate release of osteoprotegerin (OPG) from human bone cells - A contributing factor in myeloma bone loss?
por: Shipman, C, et al.
Publicado em: (2002)

Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.
por: Vanderkerken, K, et al.
Publicado em: (2003)

Bone marrow endothelial cells produce osteoprotegerin: Evidence for a role in the development of myeloma bone disease
por: De Leenheer, E, et al.
Publicado em: (2004)

Bone marrow endothelial cells express the osteoclastogenic factor RANKL and its decoy receptor OPG: Evidence for a role in the development of myeloma bone disease.
por: De Leenheer, E, et al.
Publicado em: (2002)

APOMINE (TM), a novel inhibitor of the meyalonate/isoprenoid pathway, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of the myeloma disease in vivo.
por: Croucher, P, et al.
Publicado em: (2002)

Bisphosphonates and in vivo models of multiple myeloma - Reply
por: Shipman, C, et al.
Publicado em: (2001)

Myeloma cells isolated from patients with multiple myeloma express osteoprotegerin ligand.
por: Shipman, C, et al.
Publicado em: (2000)

Osteocyte CIITA aggravates osteolytic bone lesions in myeloma
por: Huan Liu, et al.
Publicado em: (2022-06-01)

CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
por: Dongzheng Gai, et al.
Publicado em: (2022-09-01)

Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma
por: Dirk Hose, et al.
Publicado em: (2024-12-01)

Bisphosphonates--mechanisms of action in multiple myeloma.
por: Shipman, C, et al.
Publicado em: (2000)

A loss of host-derived MMP-7 promotes myeloma growth and osteolytic bone disease in vivo
por: Lwin, S, et al.
Publicado em: (2017)

Correction: Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma
por: Dirk Hose, et al.
Publicado em: (2025-01-01)

Tumour cells isolated from patients with multiple myeloma express the critical osteoclastogenic factor, RANKL.
por: Shipman, C, et al.
Publicado em: (2000)

Effect of glycosphingolipids on osteoclastogenesis and osteolytic bone diseases.
por: Ersek, A, et al.
Publicado em: (2012)

Myeloma cells can promote osteoclastic activity rather than osteoclast recruitment in vitro; Evidence from the 5T2MM murine model of myeloma
por: Mueller, G, et al.
Publicado em: (2004)

Elucidation of molecular basis of osteolytic bone lesions in advanced multiple myeloma
por: Dongyeop Shin, et al.
Publicado em: (2024-01-01)

5T2MM murine myeloma cells and CD138+ve human myeloma cells promote osteoclastic activity rather than osteoclast formation in vitro
por: Mueller, G, et al.
Publicado em: (2004)

Advances in the management of myeloma bone disease.
por: Shipman, C, et al.
Publicado em: (2005)

Osteolytic disease in IL-6 and Myc dependent mouse model of human myeloma
por: Fumou Sun, et al.
Publicado em: (2020-03-01)

LONG-ACTING ZOLEDRONIC ACID: ONCE-YEARLY ADMINISTRATION AND EFFICACY EVALUATION IN MYELOMA BONE DISEASE
por: Murat Çınarsoy
Publicado em: (2024-12-01)

Osteolytic lesions: Multiple myeloma or prostate cancer?
por: Akshitha Devaraj, MBBS, et al.
Publicado em: (2023-04-01)

Preventing osteolytic lesions and osteomyelitis in multiple myeloma
por: Aiken Dao, et al.
Publicado em: (2022-12-01)

Tumor-host cell interactions in the bone disease of myeloma.
por: Fowler, J, et al.
Publicado em: (2011)

Promotion of Bone Lesions Through the Myeloma Integrin α6-Mediated Osteolytic Signaling
por: Huan Liu, et al.
Publicado em: (2021-06-01)

Soluble rank ligand produced by myeloma cells causes generalised bone loss in multiple myeloma.
por: Clive Henry Buckle, et al.
Publicado em: (2012-01-01)

The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel.
por: Jagdev, S, et al.
Publicado em: (2001)

EZH2 serves as a viable therapeutic target for myeloma-induced osteolytic bone destruction
por: Rui Liu, et al.
Publicado em: (2025-01-01)

Multiple myeloma presenting as a massive osteolytic lesion at the clivus
por: Domingos Sousa, et al.
Publicado em: (2020-11-01)

Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
por: Shipman, C, et al.
Publicado em: (2003)

Role of Tumor-Derived Chemokines in Osteolytic Bone Metastasis
por: Salvatore J. Coniglio
Publicado em: (2018-06-01)